Opportunity Information: Apply for RFA CA 22 056
Apply for RFA CA 22 056
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396.
- This funding opportunity was created on 2022-10-03.
- Applicants must submit their applications by 2023-12-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)" is a discretionary NIH funding announcement from the National Cancer Institute (NCI), listed under Funding Opportunity Number RFA-CA-22-056 and CFDA 93.396. It uses the R01 grant mechanism and supports research in the broad activity areas of education and health, with a clear emphasis on cancer-related science that intersects with HIV and inequities in health outcomes. The key limitation is that clinical trials are not allowed under this announcement, which signals that NCI is prioritizing foundational and translational work that advances mechanistic understanding rather than testing clinical interventions in human trial formats.
The scientific focus is on cancer health disparities among people living with HIV who are also members of underrepresented minority groups. The announcement is aimed at studies that dig into biological and mechanistic interactions, meaning projects should be designed to explain "how" and "why" disparities emerge and persist at the level of pathways, tumor biology, immune function, viral-host interactions, co-infections, inflammation, treatment effects, or other underlying processes. The goal is to understand how HIV, in the context of social and structural health disparities, contributes to cancer initiation and progression and to the downstream disease consequences that follow from these cancers. NCI explicitly includes both AIDS-defining cancers and non-AIDS-defining cancers, so proposed research can address malignancies historically tied to advanced HIV disease as well as cancers increasingly seen in the era of antiretroviral therapy where chronic immune dysregulation, aging, co-morbidities, and unequal access to prevention and care may shift risk and outcomes.
Because the scope highlights "basic mechanistic or translational studies," competitive projects would typically connect laboratory or computational approaches to human-relevant questions without crossing into an interventional clinical trial. That can include studies using patient-derived specimens, tumor and immune profiling, molecular epidemiology with a mechanistic angle, viral oncology, microbiome or co-infection biology, biomarker discovery and validation, preclinical models, and other translational pipelines that could ultimately inform prevention, early detection, risk stratification, or therapeutic strategies. The emphasis on "biological interactions of cancer health disparities" suggests the institute is looking for research that does more than document inequity; it should test specific biologic hypotheses about how disadvantage, exposures, comorbid conditions, treatment differences, stress biology, or other disparity-linked factors interact with HIV to influence cancer biology and outcomes.
Eligibility is broad and includes many types of U.S. organizations and government entities, such as state, county, city or township governments, special district governments, and independent school districts. Academic institutions are eligible across public/state-controlled and private higher education. Tribal eligibility includes federally recognized Native American tribal governments as well as other tribal organizations, plus specific categories such as Tribally Controlled Colleges and Universities (TCCUs). The announcement also recognizes and encourages participation from institutions and organizations that commonly serve underrepresented populations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Nonprofits are eligible whether or not they hold 501(c)(3) status, and faith-based or community-based organizations are also listed as eligible applicants. In addition, the opportunity allows for-profit organizations (other than small businesses) and small businesses to apply, and it explicitly includes non-U.S. (foreign) organizations, regional organizations, and applicants from U.S. territories or possessions, which expands the potential applicant pool and allows research teams to address HIV-associated cancer disparities in diverse geographic and population contexts.
Key administrative details include an original closing date of 2023-12-15 and a creation date of 2022-10-03. The source data does not list an award ceiling, expected award count, or other budgetary limits in the provided fields, so applicants would typically look to the full FOA for budget guidance consistent with R01 norms and NCI policies. Overall, the opportunity is designed to stimulate rigorous, mechanistically driven science that clarifies how HIV and disparity-related factors converge to shape cancer risk, tumor behavior, progression, and harmful sequelae in underrepresented people living with HIV, building a stronger biological foundation for future strategies to reduce inequities in cancer outcomes.
FAQs: Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
What is the official title of this funding opportunity?
The opportunity is titled "Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)."
Which agency is offering this grant?
This is a discretionary NIH funding announcement from the National Cancer Institute (NCI).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-CA-22-056.
What is the CFDA number listed for this opportunity?
The CFDA number provided is 93.396.
What grant mechanism does this opportunity use?
This announcement uses the R01 grant mechanism.
Are clinical trials allowed under this FOA?
No. Clinical trials are not allowed under this announcement, indicating the focus is on basic mechanistic and translational research rather than testing clinical interventions in a human trial format.
What is the main scientific focus of this grant?
The focus is on cancer health disparities among people living with HIV who are also members of underrepresented minority groups, with an emphasis on biological and mechanistic interactions that help explain how and why disparities develop and persist.
What kinds of research questions are most aligned with the FOA?
The FOA prioritizes studies designed to explain underlying mechanisms, such as pathways and interactions involving tumor biology, immune function, viral-host interactions, co-infections, inflammation, treatment effects, and other processes that may contribute to disparities in cancer initiation, progression, and downstream consequences in underrepresented PLWH.
Does the FOA include both AIDS-defining and non-AIDS-defining cancers?
Yes. NCI explicitly includes both AIDS-defining cancers and non-AIDS-defining cancers, allowing projects to address malignancies historically associated with advanced HIV disease as well as cancers increasingly observed in the era of antiretroviral therapy.
How does the FOA frame the role of HIV in cancer disparities?
The opportunity emphasizes understanding how HIV, in the context of social and structural health disparities, contributes to cancer initiation and progression and to harmful sequelae following cancer in underrepresented people living with HIV.
What types of approaches are described as a fit for this opportunity?
Aligned projects typically connect laboratory or computational approaches to human-relevant questions without becoming an interventional clinical trial. Examples mentioned include studies using patient-derived specimens, tumor and immune profiling, molecular epidemiology with a mechanistic angle, viral oncology, microbiome or co-infection biology, biomarker discovery and validation, and preclinical models or other translational pipelines.
Is documenting disparities enough to be competitive?
The description suggests that simply documenting inequity is not the goal. The emphasis on "biological interactions of cancer health disparities" indicates interest in testing specific biological hypotheses about how disparity-linked factors interact with HIV to shape cancer biology and outcomes.
What activity areas does this funding opportunity support?
The opportunity is listed under the broad activity areas of education and health, with a clear emphasis on cancer-related science intersecting with HIV and inequities in health outcomes.
Who is eligible to apply (in general)?
Eligibility is broad and includes many types of U.S. organizations and government entities, academic institutions (public and private), tribal entities and organizations, nonprofits (with or without 501(c)(3) status), faith-based and community-based organizations, for-profit organizations (other than small businesses), and small businesses.
Are state and local government entities eligible?
Yes. Eligible applicants include state governments and local government entities such as county, city, or township governments, as well as special district governments and independent school districts.
Are academic institutions eligible to apply?
Yes. The eligible categories include both public/state-controlled institutions of higher education and private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Eligibility includes federally recognized Native American tribal governments as well as other tribal organizations, including Tribally Controlled Colleges and Universities (TCCUs).
Does the FOA encourage applications from institutions serving underrepresented populations?
Yes. The announcement recognizes and encourages participation from institutions and organizations that commonly serve underrepresented populations, including HBCUs, Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs.
Are nonprofits eligible if they do not have 501(c)(3) status?
Yes. Nonprofits are listed as eligible whether or not they hold 501(c)(3) status.
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly listed among eligible applicants.
Can for-profit organizations apply?
Yes. The opportunity allows for-profit organizations (other than small businesses) and also explicitly allows small businesses.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The eligible applicant pool explicitly includes non-U.S. (foreign) organizations and regional organizations.
Are applicants from U.S. territories or possessions eligible?
Yes. The opportunity includes applicants from U.S. territories or possessions.
What is the original closing date for this opportunity?
The original closing date listed is 2023-12-15.
What is the creation date listed for this opportunity?
The creation date listed is 2022-10-03.
Is an award ceiling or expected number of awards provided in the information shown?
No. The source information provided does not list an award ceiling, expected award count, or other budgetary limits in the relevant fields.
What is the overall goal of the opportunity?
The overall goal is to stimulate rigorous, mechanistically driven basic and translational science that clarifies how HIV and disparity-related factors converge to shape cancer risk, tumor behavior, progression, and harmful sequelae in underrepresented people living with HIV, strengthening the biological foundation for future strategies to reduce inequities in cancer outcomes.
Browse more opportunities from the same category: Education, Health
Next opportunity: Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
Previous opportunity: Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier (UC2 Clinical Trial Not Allowed)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 22 056
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 22 056) also looked into and applied for these:
| Funding Opportunity |
|---|
| NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) Apply for PAR 23 034 Funding Number: PAR 23 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01 Clinical Trial Not Allowed) Apply for RFA DE 23 013 Funding Number: RFA DE 23 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) Apply for RFA DA 24 007 Funding Number: RFA DA 24 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) Apply for PAR 23 021 Funding Number: PAR 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) Apply for PAR 22 249 Funding Number: PAR 22 249 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed) Apply for PAR 22 239 Funding Number: PAR 22 239 Agency: National Institutes of Health Category: Education, Health Funding Amount: $375,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 018 Funding Number: RFA CA 23 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) Apply for PAR 23 041 Funding Number: PAR 23 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) Apply for RFA CA 23 019 Funding Number: RFA CA 23 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) Apply for RFA DA 24 003 Funding Number: RFA DA 24 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) Apply for RFA DA 24 004 Funding Number: RFA DA 24 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) Apply for RFA DA 23 036 Funding Number: RFA DA 23 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Transformative Educational Advancement and Mentoring Network (TEAM) (R25 Clinical Trial Not Allowed) Apply for RFA CA 23 013 Funding Number: RFA CA 23 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional) Apply for RFA DA 23 059 Funding Number: RFA DA 23 059 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional) Apply for RFA DA 23 060 Funding Number: RFA DA 23 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 24 002 Funding Number: RFA DA 24 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required) Apply for RFA CA 23 020 Funding Number: RFA CA 23 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required) Apply for RFA CA 23 021 Funding Number: RFA CA 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required) Apply for RFA CA 23 022 Funding Number: RFA CA 23 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) Apply for PAR 23 052 Funding Number: PAR 23 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 22 056", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.